

(19) World Intellectual Property Organization  
International Bureau

NII-108PC

(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
WO 01/03680 A2(51) International Patent Classification<sup>7</sup>: A61K 31/00

(21) International Application Number: PCT/GB00/02623

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

9916214.1	9 July 1999 (09.07.1999)	GB
60/142,907	9 July 1999 (09.07.1999)	US
9916315.6	12 July 1999 (12.07.1999)	GB
60/142,953	12 July 1999 (12.07.1999)	US

(71) Applicants (*for all designated States except US*): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB). NEUROCHEM, INC. [CA/CA]; 7220 Frederick-Banting, Suite 100, Montreal, Quebec H4S 2A1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CLARK, Anne [GB/GB]; Diabetes Research Laboratories, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE (GB). FRASER, Paul [CA/CA]; Centre for Research into Neurodegenerative Diseases, University of Toronto, 6 Queens Park Crescent West, Toronto M5S 3H2 (CA). VERCHERE, Bruce [CA/CA]; Department of Pathology and Laboratory Medicine, British Columbia, Research Institute for Children and Women's Health, 950 West 28

Avenue, Vancouver, British Columbia (CA). GUPTA, Ajay [CA/CA]; 255 St-Louis, Pointe-Claire, Québec H9R 5L6 (CA). MIGNEAULT, David [CA/CA]; 1125 Haendel, Laval, Québec H7W 3A1 (CA). SZAREK, Walter [CA/CA]; 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6 (CA). WEAVER, Donald [CA/CA]; 27 College View Crescent, Kingston, Ontario K7M 7J8 (CA).

(74) Agents: IRVINE, Claire, Jonquil et al.; J.A. Kemp &amp; Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

(57) Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involved administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and method of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes. The invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. In particular the process prepares cells for use in a method of treating diabetes. Also provided are a culture medium comprising the inhibitor and cells for transplantation.

WO 01/03680 A2